Bibliografía del artículo
1. Dias E, Laranja FS, Miranda A, Nobrega G. Chagas disease. A clinical, epidemiologic and pathologic study. Circulation 14:1035-60, 1956.
2. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 59:526-9, 1998.
3. De Andrade AL, Zicker F, De Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, et. al. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348:1407-13, 1996.
4. Streiger M, Del Barco M, Fabbro D, Arias E, Amicone N. Longitudinal study and specific chemotherapy in children with chronic Chagas disease, residing in a low endemicity area of Argentina. Rev Soc Bras Med Trop 37:365-75, 2004.
5. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127:151-62, 1994.
6. Brener Z. Recent advances in the chemotherapy of Chagas disease. Mem Inst Oswaldo Cruz 79:149-155, 1984.
7. Cunha-Neto E, Duranti M, Gruber A, et al. Autoimmunity in Chagas' disease cardiopathy: biological relevance of a cardiac myosin-specific epitope cross-reactive to an immunodominant Trypanosoma cruzi antigen. Proc Natl Acad Sci USA 92:3541-3545, 1995.
8. Kierszenbaum F. Chagas' disease and the autoimmunity hypothesis. Clin
Microbiol Rev 12:210-23, 1999.
9. Jones EM, Colley DG, Tostes S, Reis Lopes E, Vnencak-Jones CL, McCurley TL. Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. Am J Trop Med Hyg 48:348-57, 1993.
10. Zhang L, Tarleton RL. Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis 180:480-6, 1999.
11. Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease: neglected "evidence" by evidence-base medicine. Expert Rev Anti Infect Ther 5(4):717-726, 2007.
12. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment. Ann Intern Med 144:724-734, 2006.
13. Cançado JR. Tratamento específico. In: Cardiopatía Chagásica. Cançado JR, Chuster M, (Ed.) Fundaçao Carlos Chagas, Belo Horizonte, Brazil, pp. 327-355, 1985.
14. Fabbro de Suasnabar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, et. al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 42:99-109, 2000.
15. Gallerano RR, Sosa RR. Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy. Rev Fac Cien Med Univ Nac Córdoba 57:135-162, 2000.
16. Viotti R, Vigliano C, Lococo B, Armenti H, Lapuente A, Segura E. Chronic chagasic cardiomyopathy: clinical and serologic evolution with and without benznidazole in long-term follow-up. In: XIII World Congress of Cardiology. Free Papers. Monduzzi (Ed.) pp. 697-701, 1998.
17. Cançado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44:29-37, 2002.
18. Carbalho V, Sousa E, Vila J, et al. Heart transplantation in Chagas disease, 10 years after initial experience. Circulation 94:1815-1817, 1996.
19. Schijman A, Vigliano C, Burgos J, et al. Early diagnosis of recurrence of Tripanosoma cruzi infection by polymerasa chain reaction after heart transplantation of a chronic Chagas heart disease patient. Heart and Lung Transplantation 19:1114-1117, 2000.
20. Diez M, Favaloro L, Bertolotti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas' disease reactivation and treatment follow-up in heart transplantation. Am J Transplant, in press, 2007.
21. Rivera J, Hillis LD, Levine BD. Reactivation of cardiac Chagas disease in acquired immunodeficiency syndrome. Am J Cardiol 94:1102-1103, 2004.
22. Sartori AM, Ibrahim KY, Nunes Westphalen EV, et al. Manifestations of Chagas disease (American trypanosomiasis) in patients with HIV/AIDS. Ann Trop Med Parasitol 101:31-50, 2007.
23. Lambert N, Mehta B, Walters R, Eron JJ. Chagasic encephalitis as the initial manifestation of AIDS. Ann Intern Med 144:941-943, 2006.
24. Gurtler RE, Segura EL, Cohen JE. Congenital transmission of Trypanosoma cruzi infection in Argentina. Emerg Infect Dis 9:29-32, 2003.
25. Hermann E, Truyens C, Alonso-Vega C, et al. Congenital transmission of Trypanosoma cruzi is associated with maternal enhanced parasitemia and decreased production of interferon-gamma in response to parasite antigens. J Infect Dis 189:1274-1281, 2004.
26. Moraes-Souza H. Chagas infection transmission control: situation of transfusional transmission in Brazil and other countries of Latin America. Mem Inst Oswaldo Cruz 94:419-423, 1999.
27. Pirard M, Iihoshi N, Boelaert M, Basanta P, Lopez F, Van der Stuyft P. The validity of serologic tests for Trypanosoma cruzi and the effectiveness of transfusional screening strategies in a hyperendemic region. Transfusion 45:554-561, 2005.
28. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. Valoración de la función cardiaca por angiografía radioisotópica, en pacientes con cardiopatía chagásica crónica. Arq Bras Cardiol 45:249-56, 1985.
29. Rosenbaum MB. Chagasic cardiomyopathy. Prog Cardiovasc Dis 7:199-225, 1964.
30. Andrade ZA, Andrade SG, Oliveira GB, Alonso DR. Histopathology of the conducting tissue of the heart in Chagas' myocarditis. Am Heart J 95:316-24, 1978.
31. Cançado JR. Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz 94:331-5, 1999.
32. Marin-Neto JA, Rassi Jr A, Morillo C, Avezum A, Connolly S, Sosa-Estani S, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156:37-43, 2008.
33. WHO Technical Report Series 905. Control of Chagas disease, Etiological treatment. Geneva, Switzerland, pp. 1-109, 2002.
34. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298(18):2171-81, 2007.
35. Gascón J, Albajar P, Cañas E, Flores M, Gómez i Prat J, et al. Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica. Rev Esp Cardiol 60(3):285-93, 2007.